Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 335

1.

The Breast Avastin Trial: phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer.

Bisagni G, Musolino A, Panebianco M, De Matteis A, Nuzzo F, Ardizzoni A, Gori S, Gamucci T, Passalacqua R, Gnoni R, Moretti G, Boni C.

Cancer Chemother Pharmacol. 2013 Apr;71(4):1051-7. doi: 10.1007/s00280-013-2100-6. Epub 2013 Feb 3.

PMID:
23377310
2.

North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer.

Perez EA, Hillman DW, Dentchev T, Le-Lindqwister NA, Geeraerts LH, Fitch TR, Liu H, Graham DL, Kahanic SP, Gross HM, Patel TA, Palmieri FM, Dueck AC.

Ann Oncol. 2010 Feb;21(2):269-74. doi: 10.1093/annonc/mdp512. Epub 2009 Nov 9.

3.

Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer.

Martín M, Makhson A, Gligorov J, Lichinitser M, Lluch A, Semiglazov V, Scotto N, Mitchell L, Tjulandin S.

Oncologist. 2012;17(4):469-75. doi: 10.1634/theoncologist.2011-0344. Epub 2012 Mar 30.

4.

AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.

Gianni L, Romieu GH, Lichinitser M, Serrano SV, Mansutti M, Pivot X, Mariani P, Andre F, Chan A, Lipatov O, Chan S, Wardley A, Greil R, Moore N, Prot S, Pallaud C, Semiglazov V.

J Clin Oncol. 2013 May 10;31(14):1719-25. doi: 10.1200/JCO.2012.44.7912. Epub 2013 Apr 8.

5.

Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial.

Gligorov J, Doval D, Bines J, Alba E, Cortes P, Pierga JY, Gupta V, Costa R, Srock S, de Ducla S, Freudensprung U, Mustacchi G.

Lancet Oncol. 2014 Nov;15(12):1351-60. doi: 10.1016/S1470-2045(14)70444-9. Epub 2014 Sep 28.

PMID:
25273343
6.

Phase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer.

Lück HJ, Lübbe K, Reinisch M, Maass N, Feisel-Schwickardi G, Tomé O, Janni W, Aydogdu M, Neunhöffer T, Ober A, Aktas B, Park-Simon TW, Schumacher C, Höffkes HG, Illmer T, Wagner H, Mehta K, von Minckwitz G, Nekljudova V, Loibl S.

Breast Cancer Res Treat. 2015 Jan;149(1):141-9. doi: 10.1007/s10549-014-3217-y. Epub 2014 Dec 18.

PMID:
25519041
7.

Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.

Rastogi P, Buyse ME, Swain SM, Jacobs SA, Robidoux A, Liepman MK, Pajon ER, Dy PA, Posada JG Jr, Melnik MK, Piette F, Geyer CE Jr, Mamounas EP, Wolmark N.

Clin Breast Cancer. 2011 Aug;11(4):228-34. doi: 10.1016/j.clbc.2011.04.001. Epub 2011 May 4.

PMID:
21684812
8.

Phase II study of gemcitabine and bevacizumab as first-line treatment in taxane-pretreated, HER2-negative, locally recurrent or metastatic breast cancer.

Borson R, Harker G, Reeves J, Beck T, Hager S, Horvath W, Jones M, Tillinghast G, Arrowsmith E, Harrer G, Kudrik FJ, Malamud SC, Bromund J, Zeigler H, Tai DF, Kornberg LJ, Obasaju C, Orlando M, Yardley DA.

Clin Breast Cancer. 2012 Oct;12(5):322-30. doi: 10.1016/j.clbc.2012.07.004.

PMID:
23040000
9.

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.

Miles DW, Chan A, Dirix LY, Cortés J, Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F, Harbeck N, Steger GG, Schneeweiss A, Wardley AM, Chlistalla A, Romieu G.

J Clin Oncol. 2010 Jul 10;28(20):3239-47. doi: 10.1200/JCO.2008.21.6457. Epub 2010 May 24.

10.

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.

Lang I, Brodowicz T, Ryvo L, Kahan Z, Greil R, Beslija S, Stemmer SM, Kaufman B, Zvirbule Z, Steger GG, Melichar B, Pienkowski T, Sirbu D, Messinger D, Zielinski C; Central European Cooperative Oncology Group.

Lancet Oncol. 2013 Feb;14(2):125-33. doi: 10.1016/S1470-2045(12)70566-1. Epub 2013 Jan 10.

PMID:
23312888
11.

Trastuzumab plus capecitabine and docetaxel as first-line therapy for HER2-positive metastatic breast cancer: phase II results.

Michalaki V, Fotiou S, Gennatas S, Gennatas C.

Anticancer Res. 2010 Jul;30(7):3051-4.

PMID:
20683054
12.

Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial.

Lam SW, de Groot SM, Honkoop AH, Jager A, ten Tije AJ, Bos MM, Linn SC, van den Bosch J, Kroep JR, Braun JJ, van Tinteren H, Boven E; Dutch Breast Cancer Research Group.

Eur J Cancer. 2014 Dec;50(18):3077-88.

PMID:
25459393
13.

Phase 2 trial of a novel capecitabine dosing schedule in combination with bevacizumab for patients with metastatic breast cancer.

Gajria D, Feigin K, Tan LK, Patil S, Geneus S, Theodoulou M, Norton L, Hudis CA, Traina TA.

Cancer. 2011 Sep 15;117(18):4125-31. doi: 10.1002/cncr.25992. Epub 2011 Mar 8.

14.

Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy.

Reichardt P, Von Minckwitz G, Thuss-Patience PC, Jonat W, Kölbl H, Jänicke F, Kieback DG, Kuhn W, Schindler AE, Mohrmann S, Kaufmann M, Lück HJ.

Ann Oncol. 2003 Aug;14(8):1227-33.

15.

Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.

von Minckwitz G, Puglisi F, Cortes J, Vrdoljak E, Marschner N, Zielinski C, Villanueva C, Romieu G, Lang I, Ciruelos E, De Laurentiis M, Veyret C, de Ducla S, Freudensprung U, Srock S, Gligorov J.

Lancet Oncol. 2014 Oct;15(11):1269-78. doi: 10.1016/S1470-2045(14)70439-5. Epub 2014 Sep 28.

PMID:
25273342
16.

Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.

Jones A, O'Brien M, Sommer H, Nowara E, Welt A, Pienkowski T, Rolski J, Pham ML, Perraud K, Trillet-Lenoir V.

Cancer Chemother Pharmacol. 2010 Mar;65(4):755-63. doi: 10.1007/s00280-009-1081-y. Epub 2009 Aug 9.

PMID:
19669644
17.

Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer.

Chan A, Conte PF, Petruzelka L, Tubiana-Mathieu N, Ganju V, Llombart A, Espie M, Majois F, Gil MG, Vaissiere N, Villanova G.

Anticancer Res. 2013 Jun;33(6):2657-64.

PMID:
23749924
18.

Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer.

Lang I, Inbar MJ, Kahán Z, Greil R, Beslija S, Stemmer SM, Kaufman B, Zvirbule Z, Steger GG, Messinger D, Brodowicz T, Zielinski C.

Eur J Cancer. 2012 Nov;48(17):3140-9. doi: 10.1016/j.ejca.2012.04.022. Epub 2012 May 26.

PMID:
22640829
19.

Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer.

Mackey JR, Tonkin KS, Koski SL, Scarfe AG, Smylie MG, Joy AA, Au HJ, Bodnar DM, Soulieres D, Smith SW.

Clin Breast Cancer. 2004 Oct;5(4):287-92.

PMID:
15507175
20.

Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study).

Ducreux M, Adenis A, Pignon JP, François E, Chauffert B, Ichanté JL, Boucher E, Ychou M, Pierga JY, Montoto-Grillot C, Conroy T.

Eur J Cancer. 2013 Apr;49(6):1236-45. doi: 10.1016/j.ejca.2012.12.011. Epub 2013 Jan 24.

PMID:
23352604
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk